Case Report

Fellow Eye Macular Edema Improvement after Intravitreal Bevacizumab for Radiation Retinopathy

Isis A. S. Brito, Leandro C. Zacharias, and Sérgio Luis G. Pimentel

University of São Paulo, Rua Marieta Alves 116, 04181-260 Salvador, BA, Brazil

Correspondence should be addressed to Isis A. S. Brito; isis_alice@hotmail.com

Received 15 June 2015; Revised 28 September 2015; Accepted 29 September 2015

Academic Editor: Maurizio Battaglia Parodi

Copyright © 2015 Isis A. S. Brito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Radiation retinopathy (RR) is a progressive, chronic condition directly related to the amount of radiation administered to the retina. We report a 37-year-old patient with medulloblastoma that was treated with external beam radiation and presented to us with bilateral cystoid macular edema. He was treated with monthly bevacizumab injections only in his worst seeing eye. There was a significant improvement in his fellow eye, with marked retinal thickness reduction. Therefore, we present clinical evidence of systemic absorption and fellow eye activity of the drug (bevacizumab). One must be aware of distant side effects after intravitreal injections.

1. Introduction

Radiation retinopathy (RR) is a progressive, chronic condition related to radiation treatment of tumors, and may occur in the eyes of patients who have undergone treatment for tumors involving the optic disc, young age, and diabetes. Several risk factors have been identified, including total accumulated radiation doses above 30 to 35 grays (Gy) [4–6].

Clinically, RR can be classified as proliferative or non-proliferative, and both stages can be related to macular edema, which is associated with worse visual outcomes [7]. Several treatment modalities, such as laser photoocoagulation or intravitreal triamcinolone injections [8–10], have already been tested, but intravitreal antiangiogenic injections seem to be the most currently used therapeutic option [11–17].

2. Methods: Case Report

A 37-year-old male was submitted to 2 external beam radiation cycles for central nervous system medulloblastoma treatment in 2005 that recurred after 8 years. In 2005, the total accumulated radiation doses were 54 Gy at the posterior fossa and 36 Gy at the neuroaxis, and, in 2013, the total dose was 54 Gy. The patient came to our service complaining of bilateral progressive decrease in visual acuity over the last 6 months. On ophthalmic examination, his best-corrected visual acuity (BCVA) was 0.5 (20/40) in the OD and 0.4 (20/50) in the OS. The biomicroscopy revealed posterior subcapsular cataract in both eyes. Fundus examination showed bilateral cystoid macular edema, without any detectable microangiopathy. Those findings were confirmed by fluorescein angiography and optical coherence tomography (OCT) (Figures 1 and 2).

Due to the cystoid macular edema (CME) secondary to RR, the patient was elected to bilateral intravitreal injections of bevacizumab (1.25 mg/0.05 mL). However, the patient preferred to begin treatment only in his worst seeing eye (left eye OS). After the first intravitreal injection of bevacizumab, the cystoid macular edema showed a marked improvement in the fellow eye (OD) (Figures 3 and 4), and after the second injection it had completely resolved on that eye. The central macular thickness decreased from 361 to 217 microns, and his BCVA improved by two ETDRS lines in the OD after those two intravitreal injections in the OS (Figure 6). Therefore, the patient was treated with intravitreal
bevacizumab injections only in the OS, with BCVA and macular thickness improvement after each injection and recurrence after 30 to 45 days.

3. Discussion

RR presents a challenge regarding effective treatment. Different from cases of diabetic retinopathy, where the initial damage occurs at the pericytes, RR is characterized by direct endothelial cell damage, leading to capillary nonperfusion and consequent poor therapeutic response [18].

Its pathogenesis involves mitosis aberrations at the endothelial cells and subsequent activation of a coagulation cascade related to the vascular endothelial damage. Clinically, those pathologic changes result in microaneurysms, telangiectasia, retinal neovascularization, vitreous hemorrhage, macular edema, and tractional retinal detachment [19–21].

CME is the first clinical manifestation of RR in most of the cases. It is found in up to 70% of patients receiving brachytherapy for choroidal melanoma after 12 months of follow-up [22]. The OCT is an important diagnostic tool, as it can diagnose macular changes on average 5 months earlier than the clinically established RR [23].

Treatment options for RR cases are still disappointing. Most of the literature agrees on anti-VEGF agents, especially when dealing with CME or retinal neovascularization [11–17].

In the current case reported, we opted for bevacizumab as the drug of choice, as previous reports support the use of this drug in cases of RR [11–15] and also due to its availability in our public service. The drug showed good efficacy regarding central macular thickness reduction and BCVA improvement at the injected eye (Figure 5). However, we also noted good anatomical and functional outcomes at the fellow noninjected eye (OD), with a 2-ETDRS-line BCVA improvement after 1 month of follow-up and total resolution of the CME after 2 intravitreal injections in the OS (Figure 6). Those data suggest systemic exposure after intravitreal bevacizumab, with fellow eye biological activity.

Long distance biological action after intravitreal bevacizumab injections has already been reported in diabetic retinopathy [24] and suggests systemic absorption and recirculation of the drug. Specifically in the case reported, that fact was advantageous, improving fellow eye function without injections, but may raise issues regarding the increase in risk for thromboembolic events [25].

4. Conclusion

We report a case of CME improvement after fellow eye bevacizumab injection. To our knowledge, this phenomenon has never been previously described in cases of radiation retinopathy and reinforces the systemic exposure after intravitreal injection of this drug.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

References
[1] P. T. Finger, K. J. Chin, G. Duvall, and The Palladium-103 for Choroidal Melanoma Study Group, “Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients,” Ophthalmology, vol. 116, no. 4, pp. 790.e1–796.e1, 2009.
[2] H. Krema, S. Somani, A. Sahgal et al., “Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up,” British Journal of Ophthalmology, vol. 93, no. 9, pp. 1172–1176, 2009.
[3] E. S. Gragoudas, J. M. Seddon, K. Egan et al., “Long-term results of proton beam irradiated uveal melanomas,” Ophthalmology, vol. 94, no. 4, pp. 349–353, 1987.
[4] G. C. Brown, J. A. Shields, G. Sanborn, J. J. Augsburger, P. J. Savino, and N. J. Schatz, “Radiation retinopathy,” Ophthalmology, vol. 89, no. 12, pp. 1494–1501, 1982.
[5] D. C. Chacko, “Considerations in the diagnosis of radiation injury,” The Journal of the American Medical Association, vol. 245, no. 12, pp. 1255–1258, 1981.
[6] W. M. K. Amoaku and D. B. Archer, “Cephalic radiation and retinal vasculopathy,” Eye, vol. 4, no. 1, pp. 195–203, 1990.
[7] J. L. Kinyoun, “Long-term visual acuity results of treated and untreated radiation retinopathy (An AOS thesis),” Transactions of the American Ophthalmological Society, vol. 106, pp. 325–335, 2008.
[8] N. V. Shah, S. K. Houston, A. Markoe, and T. G. Murray, “Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma,” Clinical Ophthalmology, vol. 7, pp. 1877–1882, 2013.
[9] S. J. Bakri and T. A. Larson, “The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy,” Seminars in Ophthalmology, vol. 30, no. 4, pp. 276–280, 2015.
[10] N. Horgan, C. L. Shields, A. Mashayekhi et al., “Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma,” Retina, vol. 28, no. 7, pp. 987–995, 2008.
[11] J. O. Mason III, M. A. Albert Jr., T. O. Persaud, and R. S. Vail, “Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma,” Retina, vol. 27, no. 7, pp. 903–907, 2007.
[12] A. Gupta and J. S. Muecke, “Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin),” Retina, vol. 28, no. 7, pp. 964–968, 2008.
[13] P. T. Finger and K. Chin, “Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy,” Archives of Ophthalmology, vol. 125, no. 6, pp. 751–756, 2007.
[14] P. T. Finger, “Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin),” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 4, pp. 974–977, 2008.
[15] J. M. Solano, S. J. Bakri, and J. S. Pulido, “Regression of radiation-induced macular edema after systemic bevacizumab,” Canadian Journal of Ophthalmology, vol. 42, no. 5, pp. 748–749, 2007.
[16] R. Dunavolgyi, M. Zehetmayer, C. Simader, and U. Schmidt-Erfurth, “Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection,” Clinical and Experimental Ophthalmology, vol. 35, no. 9, pp. 878–880, 2007.
[17] P. T. Finger and K. J. Chin, “Intravitreous ranibizumab (lucentis) for radiation maculopathy,” Archives of Ophthalmology, vol. 128, no. 2, pp. 249–252, 2010.
[18] G. P. Giuliani, A. Sadaka, D. M. Hinkle, and E. R. Simpson, “Current treatments for radiation retinopathy,” Acta Ophthalmologica, vol. 50, no. 1, pp. 6–13, 2011.
[19] D. B. Archer, W. M. K. Amoaku, and T. A. Gardiner, “Radiation retinopathy-clinical, histopathological, ultrastructural and experimental correlations,” Eye, vol. 5, no. 2, pp. 239–251, 1991.
[20] A. R. Irvine, J. A. Alvarado, W. M. Wara, B. W. Morris, and L. S. Wood, “Radiation retinopathy: an experimental model for the ischemic—proliferative retinopathies,” Transactions of the American Ophthalmological Society, vol. 79, pp. 103–122, 1981.
[21] E. Midena, T. Segato, M. Valenti, C. D. Angeli, E. Bertoja, and S. Piermarocchi, “The effect of external eye irradiation on choroidal circulation,” Ophthalmology, vol. 103, no. 10, pp. 1651–1660, 1996.
[22] N. Horgan, C. L. Shields, A. Mashayekhi, L. F. Teixeira, M. A. Materin, and J. A. Shields, “Early macular morphological changes following plaque radiotherapy for uveal melanoma,” Retina, vol. 28, no. 2, pp. 263–273, 2008.
[23] N. Horgan, C. L. Shields, A. Mashayekhi, and J. A. Shields, “Classification and treatment of radiation maculopathy,” Current Opinion in Ophthalmology, vol. 21, no. 3, pp. 233–238, 2010.
[24] K. Matsuyma, N. Ogata, M. Matsuoka, M. Wada, T. Nishimura, and K. Takahashi, “Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 4, pp. 379–383, 2011.
[25] F. Semeraro, F. Morescalchi, S. Duse, E. Gambicorti, M. R. Romano, and C. Costagliola, “Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview,” Expert Opinion on Drug Safety, vol. 13, no. 6, pp. 785–802, 2014.